and also presided over the 2000 opening of the Relativistic Heavy Ion Collider, an $800 million particle accelerator.
Chaudhari's background is different from that of previous directors, all of whom were physicists. "But physicists should take heart," says Richard Gambino, a former IBM colleague now at the nearby State University of New York, Stony Brook, "because he initiated several high-level physics experiments" at IBM. Gambino and Chaudhari shared a 1995 National Medal of Technology award for work in erasable magneto-optical disks.
In his new position, the 65-year-old Chaudhari will oversee a $463 million annual budget and a bevy of important facilities. He anticipates "a free and easy exchange" with residents worried about the nearby polluted Peconic River and the future of three closed reactors. He also promises to "fight the hardest I can to get additional funding" and to expand the lab's efforts in homeland security, including developing sophisticated biological and nuclear-material sensors to protect the New York harbor.
-ANDREW LAWLER

IBM Scientist to Lead Brookhaven
Industrial strength. Praveen Chaudhari takes the helm at Brookhaven in April.
Mark Walport, an expert on lupus and other autoimmune diseases, has been tapped to lead Europe's biggest biomedical charity. The Wellcome Trust announced on 30 January that Walport, a professor at Imperial College in London and a governor of the charity until last month, will take over from outgoing director Mike Dexter on 1 June.
Like his two immediate predecessors before their appointments, Walport, 50, has spent relatively little time in the public eye; he declined to speak with the press about his new post. Since 1997, the native Londoner has been head of the division of medicine at Imperial College and Hammersmith Hospital in London. Well regarded by his peers in immunology, he was also instrumental in founding the British Academy of Medical Sciences in 1999. And, as his wife, physician Julia Walport, reported in the academy's Bulletin, Walport is an avid cook and a collector of beetles, stamps, and hunting trophies.
Walport will be the first clinician to head the trust in more than a decade, notes Keith Peters, head of the School of Clinical Medicine at Cambridge University. "For that reason alone, this is a distinctive appointment," he says. At the same time, Walport is no stranger to the kinds of basic research that receive the bulk of Wellcome funding: He leads a lab that developed a knockout mouse model of lupus.
One immediate challenge for Walport will be to help the trust adjust to leaner financial times. Seven decades since its founding with money from the will of drug company founder Sir Henry Wellcome, the charity is still flush. With a $19.8 billion endowment, the trust is committed to spending more than $1 billion a year on biomedical R&D through 2005-a figure that humbles the U.K. government's $675 million budget for the Medical Research Council in 2003. But, like other private foundations, Wellcome has been buffeted by the recent slide in stock prices. Walport's pedigree may serve him well, says Peter Cotgreave, director of the lobbying group Save British Science: "Coming from a university, this fellow will have lots of experience [in] handling tight budgets."
Another challenge is to prevent U.K. bioscientists from falling far behind their generously funded colleagues across the Atlantic. The U.S. National Institutes of Health dwarfs the trust, notes Peters. "The main problem is to make sure European medical science is in a position to compete with the U.S., where the increases in research funding have been inexorable," he says.
During his tenure, Dexter coaxed the U.K. government to contribute to a major initiative to update antiquated research facilities at universities, and he spoke out on a range of issues, including the importance of making data from the Human Genome Project freely available to researchers. Walport is primed to follow that lead, insists Leszek Borysiewicz, head of Imperial's Faculty of Medicine: "He's more than persuasive." The U.K.'s biomedical community, at least, will be hanging on Walport's every word. 
